Cathie Wood’s ARK Invest executed significant portfolio adjustments on December 10, 2025, reflecting a strategic shift in investment focus. The fund manager made notable sales and purchases across several exchange-traded funds (ETFs).
A highlight of the activity was the sale of 176,093 shares of Iridium Communications, which ARK executed across three ETFs: the ARK Innovation ETF, ARK Autonomous Technology & Robotics ETF, and ARK Space Exploration & Innovation ETF. The total transaction value reached approximately $3.32 million, coinciding with a 6.3% rise in Iridium’s stock price. This sale follows a trend of Wood reducing her stake in the company consistently over recent weeks.
In addition to Iridium, ARK sold 4,166 shares of Teradyne, valued at $833,075, from the ARK Autonomous Technology & Robotics ETF. The fund also made a significant sale in the biotechnology sector, shedding 35,379 shares of Adaptive Biotechnologies for $525,731, which saw its shares rise 5.9% prior to the sale.
Furthermore, Wood continued to decrease ARK’s exposure to Ibotta, the mobile technology company, selling 11,700 shares across multiple ETFs amounting to a total of $266,292.
Despite the sell-offs, ARK demonstrated a keen interest in biotechnology by purchasing 11,342 shares of Nurix Therapeutics, valued at $221,736, through the ARK Genomic Revolution ETF. This purchase aligns with recent positive Phase 1 clinical trial data released by Nurix, concerning its Bruton’s tyrosine kinase degrader, bexobrutideg, which is currently being evaluated for blood cancer treatments.
The trading pattern indicates a deliberate strategy by Wood to transition funds away from communications and technology stocks while bolstering biotech investments. This approach showcases ARK’s adaptation to market trends, effectively reallocating capital in search of promising growth opportunities within the healthcare space.
Overall, the recent trades reflect Cathie Wood’s commitment to innovation and adaptive management of her investment portfolio, suggesting a positive outlook for potential growth in the biotech sector.